扩大的美降脂(Lovastatin)临床评估由多中心参加,按照双盲对照、饮食和安慰剂对照的方式进行,作者评估美降脂治疗8245例中度高胆固醇血症患者的效果和安全性。所有患者随机给予安慰剂或美降脂20mg,qd;40mg,qd;20mg,bid;40mg,bid,为期48周。用美降脂后出现下列持久的变化(P<0.001),剂量自20mg/d至80mg/d:低密度 The expanded clinical trial of Lovastatin, a multicenter study, was conducted in a double-blind, placebo-controlled, placebo-controlled manner in which the authors evaluated the efficacy and safety of METI in 8245 patients with moderate hypercholesterolemia. All patients were randomized to placebo or the United States lipid-lowering 20mg, qd; 40mg, qd; 20mg, bid; 40mg, bid for 48 weeks. The following long-lasting changes (P <0.001) following US lipid-lowering occurred at doses ranging from 20 mg / d to 80 mg / d: low density